1. Introduction {#sec1}
===============

Intrathecal drug delivery system (IDDS) implantation can be an efficacious tool in managing patients with spasticity, chronic malignant or nonmalignant pain \[[@B1]--[@B9]\]. Many advances in our understanding of intrathecal medication administration and steady improvements in technology have helped to shape the best practices associated with device implantation and management \[[@B10]\]. However, this intervention is not without complication. Hematoma formation, neurologic injury, system failure, infection, catheter-associated granuloma formation, opioid induced hyperalgesia, continuous cerebrospinal fluid leak, seroma formation, and postdural puncture headache (PDPH) are known complications of IDDS placement \[[@B11]--[@B17]\].

A recently published retrospective review examining the incidence of PDPH in conjunction with IDDS implantation found symptoms in nearly 23 percent of patients \[[@B11]\]. The majority of these patients were managed conservatively with standard of care noninvasive measures including bedrest, intravenous hydration, caffeine supplementation, and analgesic medication administration \[[@B18], [@B19]\]. However, some patients continued to suffer severe symptoms of PDPH warranting an interventional management approach.

Epidural blood patch (EBP) is a well-described technique used to provide relief to patients suffering from resistant or severe PDPH. There is evidence to support its efficacy in relieving postdural puncture headache \[[@B20]--[@B23]\]. However, debate still remains regarding the necessity, effectiveness, timing, and exact technique of EBP \[[@B24], [@B25]\]. EBP carries a small risk of complications including unintended dural puncture, subarachnoid spread, hematoma formation, increased intracranial pressure, and neurologic injury \[[@B26]--[@B29]\]. However, the combination of the known risks of EBP and patients who have long-term intrathecal catheters in situ prompts new consideration. There are case reports describing the application of EBP or fibrin glue patch in patients with IDDS implants in the setting of continuous cerebrospinal fluid leak \[[@B30]--[@B33]\]. There is a scarcity of published material describing the outcomes, technical details, and complications associated with epidural blood patch in the PDPH population with IDDS in place. This provides a difficult landscape from which to ascertain the best practice in managing this small but important subset of patients with PDPH.

2. Objective {#sec2}
============

The objective of the current study was to provide a detailed review of management of refractory postdural puncture headache in patients with implanted IDDS who required epidural blood patch procedures over a 20-year time frame at a single academic tertiary care medical center (Mayo Clinic, Rochester, MN).

3. Methods {#sec3}
==========

Following appropriate institutional review board (IRB) approval, we performed a retrospective cohort study based upon a 20-year chart review of clinical experience at a large academic medical center (Mayo Clinic, Rochester, MN). Patients who underwent placement of an IDDS during the period between June 1, 1989, and May 31, 2009, were included. The Mayo Clinic medical data retrieval service identified all patients who underwent implantation of an IDDS in this time frame with the use of ICD-9 codes. As described in the prior publication \[[@B11]\], a subset of patients who had symptoms consistent with PDPH was identified by examining all inpatient and outpatient clinical notes for a three-week period following IDDS implantation. This subset was examined for patients that proceeded to invasive intervention in the form of epidural blood patch. This formed the cohort.

The following data points were harvested from each medical record of the cohort: age at time of IDDS implantation, gender, indication for IDDS, date of IDDS implantation, methods of conservative PDPH management, IDDS catheter entry level, epidural blood patch level, epidural blood patch volume, interval between IDDS implantation and epidural blood patch, and preepidural blood patch skin preparation method. Improvement in headache symptoms after blood patch was recorded. Finally, each record was carefully screened for immediate and delayed post-EBP complications.

4. Results {#sec4}
==========

The medical data retrieval service returned 319 surgical reports on 285 different patients over the specified time frame. As previously reported, chart review uncovered postdural puncture headache symptoms in 73 patients (22.9%) \[[@B11]\]. Of the patients with PDPH, 15 patients had symptoms refractory to conservative treatment and required 17 epidural blood patch procedures. The complete results are summarized in [Table 1](#tab1){ref-type="table"}.

4.1. Conservative Treatments {#sec4.1}
----------------------------

All patients received a trial of at least one conservative measure. The conservative measures and their incidence of use in this cohort are as follows: bedrest (100%), intravenous hydration (67%), caffeine (67%), acetaminophen (47%), and antiemetic therapy (27%). See [Table 2](#tab2){ref-type="table"}.

4.2. Infectious Precautions {#sec4.2}
---------------------------

All epidural blood patches were performed under standard sterile technique. Three cases did not have skin preparation explicitly documented (20%). All others were completed with chlorhexidine (60%), betadine (13%), or both (7%). One patient received prophylactic intravenous antibiotics due to proceduralist preference.

4.3. Image Guidance {#sec4.3}
-------------------

All of the procedures were performed with fluoroscopic guidance to ensure proper needle positioning.

4.4. EBP Level {#sec4.4}
--------------

The blood patch was performed below the level of the IDDS catheter insertion in 94% of cases. See [Table 3](#tab3){ref-type="table"}.

4.5. EBP Blood Volume {#sec4.5}
---------------------

One procedure did not have volume administered explicitly recorded in the medical chart. The mean volume for the remaining procedures was 18.6 mL. The volume administered was determined by the development of patient reported paresthesias or a maximum volume of 20 mL.

4.6. EBP Timing {#sec4.6}
---------------

The initial blood patch was placed on median postimplantation day number 7. The range of initial blood patch timing ranged from 3 to 36 days after IDDS implantation. Two patients required repeat blood patch application---these occurred on days 15 and 28 after implant which were 3 and 8 days after the initial EBP, respectively. See [Table 4](#tab4){ref-type="table"}.

4.7. PDPH Symptom Resolution {#sec4.7}
----------------------------

All patients reviewed achieved relief of the PDPH symptoms. First-time blood patch success rate was 10/15 (67%). Two patients required repeat blood patches that were both successful (13%). Three patients (20%) were found to have persistent cerebrospinal fluid leak that required reoperation with purse-string suture placement and/or surgical fibrin glue placement at the IDDS catheter entrance site.

4.8. Complications {#sec4.8}
------------------

We found no complications directly related to performing an epidural blood patch in this cohort.

5. Discussion {#sec5}
=============

The goal of this study was to address the relative paucity of published technical data in placing an epidural blood patch in patients with refractory PDPH in the setting of a recently placed IDDS. As previously reported, the incidence of PDPH in this population is likely higher than initially believed \[[@B11]\]. Conservative measures are effective in relieving the underlying symptoms in the majority of cases. However, a portion of this population continues to have significant amount of PDPH symptomology that is deleterious to their quality of life. This series suggests that epidural blood patches can be performed in this population with a reasonable margin of safety and efficacy. We found no increased incidence of complications. There are, however, case reports in the literature of complications utilizing this technique in this population \[[@B34]\]. Given the minimal amount of data in the literature relating EBP, PDPH, and IDDS, it is difficult to estimate the true incidence of complications in this population compared with other PDPH and EBP populations.

There do not appear to be any technical nuances specific to performing an EBP in a patient with IDDS, other than avoiding direct trauma to the IDDS catheter in situ by utilizing fluoroscopy. This series would suggest that standard sterile technique with betadine or chlorhexidine skin preparation is satisfactory for infectious prophylaxis. Only one patient received intravenous prophylactic antibiotics and there were no infections observed in our dataset. It has been an effective practice to place the EBP from 1 to 4 interspaces below the site of the IDDS catheter. The volume administered varied according to development of patient reported paresthesias, but often the patient received the goal volume of twenty milliliters. The practice of performing an epidural blood patch has evolved to include higher volumes of administered blood due to data highlighting the importance of pressure paresthesia \[[@B28], [@B29]\]. Therefore, twenty milliliters may not have been an optimal volume in those patients who did not develop a pressure paresthesia. Despite this, a large majority of patients (80%) did report relief from one or two blood patches.

Epidural blood patching appears to be an effective intervention for patients who are afflicted with PDPH related to IDDS implantation. A majority of the patients obtained lasting relief after application of a single blood patch, while a small subset needed a second blood patch. This is consistent with success rates of EBP in other patient populations \[[@B22], [@B23]\]. Of the patients who did not respond initially, it appears reasonable to proceed with repeat EBP or epidural fibrin glue administration. On rare occasions, patients may require operative intervention with dural repair or revision.

*Limitations*. This study has recognizable limitations. Although our dataset spans a time frame of 20 years, it includes only 15 patients in our cohort. It is difficult to extrapolate to an entire population based on this sample size. Secondly, a retrospective chart review study design is not sufficient to establish any cause-effect relationship, but it would be very difficult to construct a randomized, prospective trial to assess the effectiveness of this intervention. Lastly, this dataset includes a compilation of several proceduralists with varying preferences in their procedural technique. It is impossible to control for individual preference retrospectively and this makes the interpretation of the results more difficult.

6. Conclusions {#sec6}
==============

In conclusion, this study has evaluated the largest known-to-date cohort of patients with PDPH after IDDS implant and provided a technical report on how these patients have been managed with EBP. EBP appears to be an effective intervention in this subset of PDPH patients and no complications were observed utilizing the techniques as outlined above. Repeat blood patches or epidural fibrin glue administration may be helpful for patients who do not respond to initial EBP.
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###### 

Summary of results.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient    Age   Gender   Indication                       Conservative treatments   Catheter level   EBP level   Image guidance?   Volume (mL)   POD\#   Skin prep     Complications
  ---------- ----- -------- -------------------------------- ------------------------- ---------------- ----------- ----------------- ------------- ------- ------------- ---------------
  1          54    M        Multiple sclerosis               1, 2, 3, 5                L1-2             L2-3        Yes               20            4       ChloraPrep    None

  2          49    F        Ovarian cancer                   1, 2, 3, 4, 5             L4-5             L5-S1       Yes               20            5       ChloraPrep    None

  3          57    M        Multiple sclerosis               1                         L2-3             L3-4        Yes               20            36      ChloraPrep    None

  4          49    F        Spasticity; spinal cord injury   1, 2, 3, 4, 5, 6          L3-4             L4-5        Yes               12            13      ChloraPrep    None

  5^*∗*^     54    M        Prostate cancer                  1, 2, 3                   T10-11           T10-11      Yes               15            16      Bacitracin    None

  6          45    F        Multiple sclerosis               1                         L2-3             L4-5        Yes               20            3       ChloraPrep    None

  7^*∗∗*^    72    M        Lung cancer                      1, 2                      L1-2             L3-4\       Yes               15\           20\     ChloraPrep    None
                                                                                                        L5-S1                         20            28                    

  8          45    F        Breast cancer                    1, 3, 5                   L2-3             L4-5        Yes               20            8       ChloraPrep\   None
                                                                                                                                                            Betadine      

  9          43    M        Spasticity; spinal cord injury   1, 2, 3                   L2-3             L4-5        Yes               20            7       ChloraPrep    None

  10         49    M        Pancreatic cancer                1, 2, 3, 4                L3-4             L5-S1       Yes               20            3       ChloraPrep    None

  11^*∗∗*^   30    M        Spasticity; spinal cord injury   1, 2, 3, 4, 5             L3-4             L4-5\       Yes               20\           12\     Betadine      None
                                                                                                        L4-5                          22            15                    

  12         34    F        Melanoma                         1                         L2-3             L3-4        Yes               18            14      Unknown       None

  13         50    F        Pancreatic cancer                1, 2, 3, 5                L1-2             L5-S1       Yes               15            7       ChloraPrep    None

  14         43    F        Multiple sclerosis               1, 2, 3, 5                L2-3             L3-4        Yes               20            6       Betadine      None

  15         53    F        Multiple sclerosis               1                         L3-4             L5-S1       Yes               Unknown       7       Unknown       None
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Key: conservative treatments:

\(1\) Bedrest.

\(2\) IV fluids.

\(3\) Caffeine.

\(4\) Antiemetics.

\(5\) Acetaminophen.

\(6\) Opioids.

^*∗*^Patient found to have persistent CSF leak despite initial blood patching. Ultimately required reopening of the incision and placement of a purse-string stitch and/or fibrin glue along the catheter insertion site.

^*∗∗*^Transient relief after initial blood patch. Blood patch was repeated and symptoms resolved.

###### 

Incidence of conservative treatments.

  Number of conservative treatments employed   Incidence
  -------------------------------------------- ------------
  1                                            27% (4/15)
  2                                            7% (1/15)
  3                                            20% (3/15)
  4+                                           47% (7/15)

###### 

Location of epidural blood patch.

  Location of EBP relative to IDDS catheter   Incidence
  ------------------------------------------- ------------
  At IDDS insertion site                      6% (1/17)
  1 level below                               47% (8/17)
  2 levels below                              35% (6/17)
  3 or more levels below                      12% (2/17)

###### 

Timing of epidural blood patch after IDDS implant.

  Time of EBP after IDDS implant   Incidence
  -------------------------------- ------------
  1--7 days                        53% (8/15)
  8--14 days                       27% (4/15)
  15+ days                         20% (3/15)
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